Inclusion criteria：  A clear history of acetaminophen (or acetaminophen-containing drugs) ingestion. Plasma and/or urine testing for acetaminophen components if history of ingestion is unclear. Monitoring of Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU/L at any time after APAP administration and Roussel Uclaf Causality Assessment Method(RUCAM) score > 6 Age ≥ 14 years old The subject or guardian agrees to participate in this project and signs an informed consent form.  Exclusion criteria：  The use of drugs for which frequency of adverse reactions to liver damage is defined as "common or very common" (≥1%) in the instructions. Concurrent use of herbs that are clearly susceptible to liver damage (see list of definitions in the Annex). Have a known definite cause of liver damage: active viral hepatitis; alcoholic liver disease; autoimmune liver disease; primary or secondary liver tumors; and other underlying liver disease that has affected liver function. Those who fail to provide complete general information and clinical information. Subjects or guardians who do not agree to see this project do not sign the informed consent form.